{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene+expression+study&page=4", "query": { "intervention": "Gene expression study", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 780, "total_pages": 78, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene+expression+study&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene+expression+study&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T13:58:49.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04589117", "title": "Expressive Writing for COVID-19 Resilience for Parents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Parents During COVID-19" ], "interventions": [ { "name": "Expressive writing", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-05-27", "completion_date": "2020-08-02", "has_results": false, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589117" }, { "nct_id": "NCT00601718", "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "GENETIC" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601718" }, { "nct_id": "NCT01625143", "title": "Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "B-cell Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 40, "start_date": "2012-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625143" }, { "nct_id": "NCT07050433", "title": "COMPASS Study for Metastatic Castration-resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "CXCR2 as a biomarker", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2025-08-07", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 4, "location_summary": "San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07050433" }, { "nct_id": "NCT00082017", "title": "UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large-Cell, Ki-1", "Lymphoma, T-Cell" ], "interventions": [ { "name": "UCN-01 (7-hydroxystaurosporine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 20, "start_date": "2004-04-05", "completion_date": "2011-09-27", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082017" }, { "nct_id": "NCT02285062", "title": "Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 570, "start_date": "2015-02-17", "completion_date": "2022-07-28", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 22, "location_summary": "Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285062" }, { "nct_id": "NCT01005277", "title": "Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Promyelocytic Leukemia With PML-RARA", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia", "Childhood Acute Myeloid Leukemia in Remission", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2000, "start_date": "2002-04-17", "completion_date": null, "has_results": false, "last_update_posted_date": "2022-07-14", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005277" }, { "nct_id": "NCT06692907", "title": "Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Escherichia Infection" ], "interventions": [ { "name": "B7A (ETEC challenge strain)", "type": "OTHER" }, { "name": "CssBA", "type": "BIOLOGICAL" }, { "name": "dmLT", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 72, "start_date": "2025-03-31", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Cincinnati, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06692907" }, { "nct_id": "NCT06727565", "title": "Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2025-02-18", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 3, "location_summary": "St Louis, Missouri • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06727565" }, { "nct_id": "NCT05317000", "title": "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Combination 5-azacytidine and nivolumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Burtness", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-03-23", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-22T13:58:49.468Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05317000" } ] }